Skip to main content
Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.89
+0.12 (1.37%)
At close: Feb 26, 2026

Merdury Biopharmaceutical Revenue

Merdury Biopharmaceutical had revenue of 246.00K TWD in the twelve months ending June 30, 2025, down -95.72% year-over-year. In the year 2024, Merdury Biopharmaceutical had annual revenue of 4.96M with 380.45% growth.

Revenue (ttm)
246.00K
Revenue Growth
-95.72%
P/S Ratio
15,121.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.72B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20244.96M3.93M380.45%
Dec 31, 20231.03M-1.65M-61.46%
Dec 31, 20222.68M--
Dec 31, 2021---
Dec 31, 2020---
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Orient EuroPharma 4.53B
Easywell Biomedicals 588.89M
LIWANLI Innovation 125.54M
Maywufa Company 1.58B
PhytoHealth 138.46M
Johnson Chemical Pharmaceutical Works 567.06M
Golden Biotechnology 44.58M
Allied Biotech 821.81M
Revenue Rankings